Mozobil (plerixafor) Coverage
Customize your policy alerts
Sign up for Hawaii Medical Service Association (HMSA) Policy 03-2026 alerts
Get alerted when Policy 03-2026 changes without checking for updates manually.
Monitor payer policy activity
This policy governs HMSA coverage and prior authorization for plerixafor used to mobilize hematopoietic stem cells for collection and subsequent transplantation or gene therapy protocols. It applies to members in the HMO, PPO, and QUEST lines of business when the coverage criteria and applicable benefit requirements are met.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.